Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.
Scientists at St. Jude Children's Research Hospital have revealed previously unappreciated roles for the retrotransposon LINE-1 in shaping the cancer genome structure and regulation.